BioSpace News Archive

Arena Pharmaceuticals, Inc. will present preclinical and early clinical development data from its investigative drug candidate olorinab at the Crohn’s & Colitis Congress® in Las Vegas, NV.

2-week-old Le Bonheur patient is world’s first to receive device after recent FDA approval

Greene Tweed announced that it has received a 2017 Boeing Performance Excellence Award.

Concussion! Everyone gets a head knock. Have you ever had a head knock? But was it a concussion?

Anika Therapeutics, Inc. announced that the Company plans to issue its fourth-quarter and full-year 2018 financial results after the close of the market on Thursday, February 21, 2019 and hold its investor conference call on the same day, Thursday, February 21, 2019, at 5:00 p.m. ET to discuss its financial results, business highlights, and outlook.

Lonza and AllCells have entered into a private label partnership for the manufacture and global commercialization of an extensive range of hematopoietic primary cells. This partnership expands Lonza’s broad offering of hematopoietic cell lines and enables cell biologists to easily access a wide selection of high-quality cells to boost their scientific research.

Health-science nutrition company Liquid I.V. has donated over 1 million servings of their hydration product to communities in need around the world – a number they reached this week on the heels of their rapid growth in 2018.

Bowes, M.D., Marilyn Zabielinski, M.D. and the medical team at Bowes Dermatology by Riverchase are proud to announce the availability of a revolutionary, minimally invasive facial lifting procedure, Silhouette InstaLift® at Bowes Dermatology by Riverchase.

Five Prime Therapeutics, Inc., a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, will report its fourth quarter and full year 2018 financial results on Tuesday, February 26, 2019, after the U.S. financial markets close.

Myomo, Inc. announced that it is proposing to offer and sell, subject to market conditions, shares of its common stock in an underwritten public offering.